Recruitment into Phase 2b clinical trial for scabies complete

Melbourne, Australia, 24 October 2024 – Atticus Medical Pty Ltd, a leader in the development of pharmaceuticals with a focus on social impact, is excited to announce the completion of participant recruitment for a clinical trial evaluating moxidectin as a groundbreaking treatment for scabies. This achievement is a significant step forward in our mission to develop innovative treatments for parasitic infections that impact millions of people worldwide.

The clinical trial recruited participants in the United States and Central America to test the safety and efficacy of three different doses of moxidectin in treating scabies (NCT05875441). Data from the trial will allow selection of a suitable dose for planned Phase 3 clinical studies. Medicines Development for Global Health are the sponsors of the trial with financial support provided by Atticus Medical as part of the companies’ collaborative effort to make new medicines available to people in high-, low-and middle-income countries.

Dr John Lambert, Atticus’ General Manager commented, “Completing recruitment in this trial marks the achievement of an important milestone in the further development of moxidectin and we keenly await both receiving and reporting the results of the data analysis.”

- END

‍

About Atticus Medical Pty Ltd

Atticus Medical is dedicated to developing innovative pharmaceutical solutions that address globally unmet medical needs. With a strong emphasis on research and development, Atticus Medical aims to make a positive impact through its cutting-edge therapies and commitment to affordable healthcare.

‍

For further information, please contact:

Dr John Lambert, General Manager

Atticus Medical Pty Ltd

info@atticusmed.com

www.atticusmed.com